Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The aims of this prospective study were to investigate temporal changes in mood status and distress level, as well as the development of depression, during pegylated interferon (PEG-IFN)-based treatment of patients with chronic hepatitis C (CHC). We also explored whether baseline demographic, psychiatric, and personality traits predicted the evolution of depression. Methods: CHC patients without depression were screened with laboratory tests; psychiatric interviews; and evaluations of mood symptoms, level of distress, and personality traits. A total of 67 treatment-naïve patients with CHC were consecutively treated with PEG-IFN-α-2a plus ribavirin for 48 (genotype 1, n=29) or 24 (genotype 2, n=38) weeks. Patients were followed prospectively every 4 weeks during the treatment period. Results: Seven patients (10.4%) were diagnosed with major depressive disorder (MDD), and eight (11.9%) developed subsyndromal depression. Times to onset of MDD and subsyndromal depression were 6.67±5.01 and 11.11±5.58 weeks, respectively, after initiation of treatment. Patients who developed MDD had significantly increased fatigue and anxiety and poor psychological well-being during the course of treatment. Pretreatment subthreshold mood symptoms were a significant predictor of depression. Conclusion: An early psychiatric assessment may be helpful in improving psychological well-being in those with CHC, leading to adherence to PEG-IFN-based treatment.
Abstract
Objective: The aims of this prospective study were to investigate temporal changes in mood status and distress level, as well as the development of depression, during pegylated interferon (PEG-IFN)-based treatment of patients with chronic hepatitis C (CHC). We also explored whether baseline demographic, psychiatric, and personality traits predicted the evolution of depression. Methods: CHC patients without depression were screened with laboratory tests; psychiatric interviews; and evaluations of mood symptoms, level of distress, and personality traits. A total of 67 treatment-naïve patients with CHC were consecutively treated with PEG-IFN-α-2a plus ribavirin for 48 (genotype 1, n=29) or 24 (genotype 2, n=38) weeks. Patients were followed prospectively every 4 weeks during the treatment period. Results: Seven patients (10.4%) were diagnosed with major depressive disorder (MDD), and eight (11.9%) developed subsyndromal depression. Times to onset of MDD and subsyndromal depression were 6.67±5.01 and 11.11±5.58 weeks, respectively, after initiation of treatment. Patients who developed MDD had significantly increased fatigue and anxiety and poor psychological well-being during the course of treatment. Pretreatment subthreshold mood symptoms were a significant predictor of depression. Conclusion: An early psychiatric assessment may be helpful in improving psychological well-being in those with CHC, leading to adherence to PEG-IFN-based treatment.
참고문헌 (49)
- Global Burden Of Hepatitis C Working Group, "Global burden of disease (GBD) for hepatitis C", J Clin Pharmacol, 44, pp.20~29 (2004)
- Nelson DR., "The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients", Liver Int, 31(Suppl 1), pp.53~57 (2011)
- Schaefer M, "Interferon alpha(IFNalpha)and psychiatric syndromes : a review", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.731~746 (2002)
- Dieperink E, "Neuropsychiatric symptoms associated with hepatitis C and interferon alpha : a review", Am J Psychiatry, 157, pp.867~876 (2000)
- Hauser P, "A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C", Mol Psychiatry, 7, pp.942~947 (2002)
- Lotrich FE, "Depression following pegylated interferon-alpha : characteristics and vulnerability", J Psychosom Res, 63, pp.131~135 (2007)
- Rowan PJ, "Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C", J Clin Gastroenterol, 38, pp.530~534 (2004)
- Leutscher PD, "Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C", Hepatology, 52, pp.430~435 (2010)
- Raison CL, "Depression during pegylated interferon-alpha plus ribavirin therapy : prevalence and prediction", J Clin Psychiatry, 66, pp.41~48 (2005)
- Patterson AL, "Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?", Gen Hosp Psychiatry, 33, pp.354~362 (2011)
- Loftis JM, "Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C : a 16-week prospective study", J Psychosom Res, 74, pp.57~63 (2013)
- Horikawa N, "Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy : a prospective study", Gen Hosp Psychiatry, 25, pp.34~38 (2003)
- Malaguarnera M, "Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C", J Interferon Cytokine Res, 21, pp.273~278 (2001)
- Wichers MC, "Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes", Psychol Med, 35, pp.433~441 (2005)
- Baranyi A, "A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection", Psychother Psychosom, 82, pp.332~340 (2013)
- Schaefer M, "Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease : a randomized trial", Ann Intern Med, 157, pp.94~103 (2012)
- Udina M, "Interferon-induced depression in chronic hepatitis C : a systematic review and meta-analysis", J Clin Psychiatry, 73, pp.1128~1138 (2012)
- Beck AT, "An inventory for measuring depression", Arch Gen Psychiatry, 4, pp.561~571 (1961)
- Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
- Beck AT, "An inventory for measuring clinical anxiety : psychometric properties", J Consult Clin Psychol, 56, pp.893~897 (1988)
- Kim EJ, "Reliabilities and Validities of the POMS (Profile of Mood States, Korean Edition) for the Normal High School and College Students", M. Sc, Department of Medicine, pp.2001
- Steer RA, "Self-reported depressive symptoms that differentiate recurrent-episode major depression from dysthymic disorders", J Clin Psychol, 43, pp.246~250 (1987)
- Kim JH, "The reliability and validity test of psychosocial well-being index(PWI)", J Korean Acad Nurs, 29, pp.304~313 (1999)
- Derose S., "Understanding Health Care Outcomes Research", pp.175~209 (1997), Aspen
- Min BM, "NEO-PI-R", PSI Consulting, ~ (1997)
- 유태용, "성격의 5요인과 조직에서의 맥락수행간의 관계", 한국심리학회지: 산업 및 조직, 15(2), pp.1~24 (2002), 한국산업및조직심리학회
- Costa PT, "Normal personality assessment in clinical practice : the NEO Personality Inventory", Psychol Assess, 4, pp.5~13 (1992)
- Papastylianou A, "Relating on the internet, personality traits and depression: research and implications", Eur J Couns Psychol, 2, pp.65~78 (2013)
- Hwang JY, "Multidimensional comparison of personality characteristics of the Big Five model, impulsiveness, and affect in pathological gambling and obsessive-compulsive disorder", J Gambl Stud, 28, pp.351~362 (2012)
- Chung YO, "A study of factor structures of the Barratt impulsiveness scale in Korean university students", Korean J Clin Psychol, 16, pp.111~114 (1997)
- Lee HS, "Impulsivity Test", Korea Guidance, ~ (1992)
- Barratt ES, "Anxiety and impulsiveness related to psychomotor efficiency", Percept Mot Skills, 9, pp.191~198 (1959)
- Patton JH, "Factor structure of the Barratt impulsiveness scale", J Clin Psychol, 51, pp.768~774 (1995)
- Carver CS, "Behavioral-inhibition, behavioral activation, and affective responses to impending reward and punishment - the bis bas scales", J Per Soc Psychol, 67, pp.319~333 (1994)
- Bedossa P, "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group", Hepatology, 24, pp.289~293 (1996)
- Joo SK, "Prospective comparison of noninvasive fibrosis assessment to predict advanced fibrosis or cirrhosis in Asian patients with hepatitis C", J Clin Gastroenterol, 49, pp.697~704 (2015)
- Laird NM, "Random-effects models for longitudinal data", Biometrics, 38, pp.963~974 (1982)
- Cnaan A, "Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data", Stat Med, 16, pp.2349~2380 (1997)
- Verbeke G, "Linear Mixed Models for Longitudinal Data" (2009), Springer Verlag
- Chapman J, "Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-alpha and ribavirin therapy : a prospective evaluation", Am J Gastroenterol, 106, pp.2123~2132 (2011)
- Bonaccorso S, "Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus", J Affect Disord, 72, pp.237~241 (2002)
- Shakoor A, "Frequency of depression and somatic symptoms in patients on interferon alpha", ribavirin for chronic hepatitis C, 2010, pp.22, 6~9
- Bernstein D, "Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients", Hepatology, 35, pp.704~708 (2002)
- Karaivazoglou K, "Fatigue and depressive symptoms associated with chronic viral hepatitis patients. health-related quality of life (HRQOL)", Ann Hepatol, 9, pp.419~427 (2010)
- Faul LA, "Relationship of stress management skill to psychological distress and quality of life in adults with cancer", Psychooncology, 19, pp.102~109 (2010)
- Hartl K, "Personality traits and psychosocial stress : quality of life over 2 years following breast cancer diagnosis and psychological impact factors", Psychooncology, 19, pp.160~169 (2010)
- Neri S, "A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin", J Clin Gastroenterol, 44, pp.e210~e217 (2010)
- Castellvi P, "Pegylated interferon and ribavirin-induced depression in chronic hepatitis C : role of personality", J Clin Psychiatry, 70, pp.817~828 (2009)
- Lotrich FE, "Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism", Biol Psychiatry, 65, pp.344~348 (2009)